Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.

Purpose: Patients with advanced biliary tract cancers (BTCs) have a dismal prognosis. This multisite, single-institution study analyzed the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with advanced BTC.

Materials And Methods: The prospectively maintained institutional database was searched for patients with advanced BTC.

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.

Purpose: Clinical-pathologic features and natural history of patients with ()-mutant intrahepatic cholangiocarcinoma (CCA) are not well characterized. Here, we sought to describe the natural history, clinical phenotype, and prognostic impact of advanced, -mutated CCA.

Methods: We conducted a multicentric, retrospective analysis of patients with -mutated (IDH1 or IDH2) CCA between 2010 and 2020.

Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer.

Background: The symptom burden associated with cancer and its treatment can negatively affect patients' quality of life and survival. Symptom-focused collaborative care model (CCM) interventions can improve outcomes, but only if patients engage with them. We assessed the receptivity of severely symptomatic oncology patients to a remote nurse-led CCM intervention.

TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies.

TAS-102 is an orally administered fixed-dose formulation consisting of trifluorothymidine (TFT), a fluoropyrimidine antimetabolite, and tipiracil (TPI), an inhibitor of thymidine phosphorylase (TP) that prevents rapid degradation of TFT and ensures its bioavailability. The novelty of TAS-102 lies in its antitumor activity against 5-fluorouracil (5-FU) resistant tumors, demonstrated both in the in vitro models and xenografts. The cytotoxic activity of TFT relies primarily on extensive incorporation of the TFT metabolite into the cellular DNA inducing DNA dysfunction and cell death.

Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013.

Objective  To show the recent trends in thyroid cancer in the United States, elucidate the characteristics of stage IV thyroid cancer, and consider the effects of diagnostic testing on the rising incidence of thyroid cancer. Design  A retrospective population-based study conducted using the National Cancer Database from 2000-2013 (NCDB). Demographics of patients presenting with stage IV thyroid cancer were compared to patients presenting with all other stages using the chi-square testing.